0,1,2,3,4,5
endemic areas.,,,,,
,Table 1. MERS-CoV vaccine candidates grouped according to category.,,,,
,Humoral,,,,
Vaccine Type,,Cell-Mediated,Protective in:,Clinical Trial,Source (s)
,Response in:,,,,
,,Response in:,,,
Subunit,,,,,
RBD,"M, P","M, P","M, P",,"[50,55,58]"
S nanoparticles,M,,M,,[61]
Prefusion-locked S,M,,,,[34]
NTD,M,M,M,,[65]
DNA,,,,,
pVax1-S,"M, P, C","M, P",P,Phase I,[71]
pVRC8400-S 1,"M, P",,P,,[74]
pcDNA3.1(+)-S1 or S,M,M,M,,"[75,77]"
Viral Vector,,,,,
VEEV-S,M,,,,[38]
VEEV-N,,M,M,,[82]
MVA-S,"M, C",M,"M, C",Phase I,[88]
Ad5-S or S1,M,M,,,"[93,94]"
Ad5-S 2,M,M,M,,[96]
Ad41-S,M,M,,,[94]
ChAdOx1-S,M,M,M,Phase I,[102]
MVvac2-S,M,M,M,,[104]
Newcastle-S,"M, C",,,,[107]
VSV-S,"M, P",P,,,[109]
Rabies-S1,M,,M,,[111]
"Bac-S,E,M",P,P,,,[113]
Bac-RBD+VP2,M,M,,,[114]
Whole,,,,,
Formalin inactivated,M,,M,,[117]
MERS-âˆ†E,,,,,[122]
MERS-dNSP16,M,,M,,[127]
MERS-dORF3-5,M,,M,,[129]
,"Humoral response denotes any antibody response generated,",,,in most cases a NAb response. Cell-mediated,
